Growth hormone treatment reduces abdominal visceral fat in postmenopausal women with abdominal obesity: A 12-month placebo-controlled trial

Journal of Clinical Endocrinology and Metabolism

Volumn 90, Issue 3, 2005, Pages 1466-1474

  Franco, Celina ^a   Brandberg, John ^a   Lönn, Lars ^a   Andersson, Björn ^a   Bengtsson, Bengt Åke ^a   Johannsson, Gudmundur ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

FAT; HUMAN GROWTH HORMONE; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; CHOLESTEROL; SOMATOMEDIN C;

ABDOMEN; ADULT; ARTHRALGIA; ARTICLE; BODY FAT; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FAT CONTENT; FEMALE; FLUID RETENTION; GLUCOSE CLAMP TECHNIQUE; HAIR LOSS; HUMAN; INSULIN SENSITIVITY; INTERMETHOD COMPARISON; JOINT STIFFNESS; LEG MUSCLE; LIVER; OBESITY; PARESTHESIA; PERIPHERAL EDEMA; POSTMENOPAUSE; PRIORITY JOURNAL; PYELONEPHRITIS; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SIDE EFFECT; SWEATING; THIGH; TIME SERIES ANALYSIS; VISCERA; ADIPOSE TISSUE; BODY COMPOSITION; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; INSULIN RESISTANCE; METABOLISM; MIDDLE AGED; MOTOR ACTIVITY; PATIENT COMPLIANCE; QUALITY OF LIFE;

ABDOMEN; ADIPOSE TISSUE; BLOOD GLUCOSE; BODY COMPOSITION; CHOLESTEROL; FEMALE; GLUCOSE INTOLERANCE; HUMAN GROWTH HORMONE; HUMANS; INSULIN RESISTANCE; INSULIN-LIKE GROWTH FACTOR I; MIDDLE AGED; MOTOR ACTIVITY; OBESITY; PATIENT COMPLIANCE; PLACEBOS; POSTMENOPAUSE; QUALITY OF LIFE; VISCERA;

EID: 15944394754     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2004-1657     Document Type: Article

References (53)

1. Wajchenberg BL 2000 Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev 21:697-738
2. Alberti KG, Zimmet PZ 1998 Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15: 539-553
3. Meigs JB 2002 Epidemiology of the metabolic syndrome, 2002. Am J Manag Care 8:5283-5292; quiz S293-S296
4. Grundy SM 2002 Obesity, metabolic syndrome, and coronary atherosclerosis. Circulation 105:2696-2698
5. Bouchard C, Despres JP, Mauriege P 1993 Genetic and nongenetic determinants of regional fat distribution. Endocr Rev 14:72-93
6. Ford E, Giles W, Dietz W 2002 Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA 287:356-359
7. Hubert HB, Feinleib M, McNamara PM, Castelli WP 1983 Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation 67:968-977
8. Suk SH, Sacco RL, Boden-Albala B, Cheun JF, Pittman JG, Elkind MS, Paik MC; Northern Manhattan Stroke Study 2003 Abdominal obesity and risk of ischemic stroke: the Northern Manhattan Stroke Study. Stroke 34:1586-1592
9. Yu AS, Keeffe EB 2002 Nonalcoholic fatty liver disease. Rev Gastroenterol Disord 2:11-19
10. Bjorntorp P 1993 Visceral obesity: a "civilization syndrome". Obes Res 1:206-222
11. Bengtsson BA, Rosén T, Johansson JO, Johannsson G, Oscarsson J, Landin-Wilhelmsen K 1995 Cardiovascular risk factors in adults with growth hormone deficiency. Endocrinol Metab 2(Suppl B):29-35
12. Vahl N, Jorgensen JO, Skjaerbaek C, Veldhuis JD, Orskov H, Christiansen JS 1997 Abdominal adiposity rather than age and sex predicts mass and regularity of GH secretion in healthy adults. Am J Physiol 272:E1108-E1116
13. Veldhuis JD, Iranmanesh A 1996 Physiological regulation of the human growth hormone (GH)-insulin-like growth factor type I (IGF-I) axis: predominant impact of age, obesity, gonadal function, and sleep. Sleep 19:5221-5224
14. Clasey JL, Weltman A, Patrie J, Weltman JY, Pezzoli S, Bouchard C, Thorner MO, Hartman ML 2001 Abdominal visceral fat and fasting insulin are important predictors of 24-hour GH release independent of age, gender, and other physiological factors. J Clin Endocrinol Metab 86:3845-3852
15. Bengtsson BA, Johannsson G 1999 Effect of growth-hormone therapy on early atherosclerotic changes in GH-deficient adults. Lancet 353:1898-1899
16. Bengtsson BA, Johannsson G 1998 The use of growth hormone in adults: a review of the last 10 years, the present and a perspective for the future. Growth Horm IGF Res 8(Suppl B):27-35
17. Johannsson G, Marin P, Lonn L, Ottosson M, Stenlof K, Bjorntorp P, Sjostrom L, Bengtsson BA 1997 Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure. J Clin Endocrinol Metab 82:727-734
18. Richelsen B, Pedersen SB, Borglum JD, Moller-Pedersen T, Jorgensen J, Jorgensen JO 1994 Growth hormone treatment of obese women for 5 wk: effect on body composition and adipose tissue LPL activity. Am J Physiol 266:E211-E216
19. Taaffe DR, Thompson JL, Butterfield GE, Hoffman AR, Marcus R 2001 Recombinant human growth hormone, but not insulin-like growth factor-I, enhances central fat loss in postmenopausal women undergoing a diet and exercise program. Horm Metab Res 33:156-162
20. Tomlinson JW, Stewart PM 2001 Cortisol metabolism and the role of 11β-hydroxysteroid dehydrogenase. Best Pract Res Clin Endocrinol Metab 15:61-78
21. Albert SG, Mooradian AD 2004 Low-dose recombinant human growth hormone as adjuvant therapy to lifestyle modifications in the management of obesity. J Clin Endocrinol Metab 89:695-701
22. Bosaeus I, Johannsson G, Rosen T, Hallgren P, Tolli J, Sjostrom L, Bengtsson BA 1996 Comparison of methods to estimate body fat in growth hormone deficient adults. Clin Endocrinol (Oxf) 44:395-402
23. Chowdhury B, Sjostrom L, Alpsten M, Kostanty J, Kvist H, Lofgren R 1994 A multicompartment body composition technique based on computerized tomography. Int J Obes Relat Metab Disord 18:219-234
24. Ricci C, Longo R, Gioulis E, Bosco M, Pollesello P, Masutti F, Croce LS, Paoletti S, de Bernard B, Tiribelli C, Dalla Palma L 1997 Noninvasive in vivo quantitative assessment of fat content in human liver. J Hepatol 27:108-113
25. Piekarski J, Goldberg HI, Royal SA, Axel L, Moss AA 1980 Difference between liver and spleen CT numbers in the normal adult: its usefulness in predicting the presence of diffuse liver disease. Radiology 137:727-729
26. DeFronzo RA, Tobin JD, Andres R 1979 Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237:E214-E223
27. 1997 American Diabetes Association: clinical practice recommendations 1997. Diabetes Care 20(Suppl 1):S1-S70
28. Haffner SM, Kennedy E, Gonzalez C, Stern MP, Miettinen H 1996 A prospective analysis of the HOMA model. The Mexico City Diabetes Study. Diabetes Care 19:1138-1141
29. Landin-Wilhelmsen K, Wilhelmsen L, Lappas G, Rosen T, Lindstedt G, Lundberg PA, Bengtsson BA 1994 Serum insulin-like growth factor I in a random population sample of men and women: relation to age, sex, smoking habits, coffee consumption and physical activity, blood pressure and concentrations of plasma lipids, fibrinogen, parathyroid hormone and osteocalcin. Clin Endocrinol (Oxf) 41:351-357
30. Friedewald WT, Levy RI, Fredrickson DS 1972 Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499-502
31. Baecke JA, Burema J, Frijters JE 1982 A short questionnaire for the measurement of habitual physical activity in epidemiological studies. Am J Clin Nutr 36:936-942
32. Dupuy HJ 1984 The psychological general well-being (PGWB) index. In: Wenger NK, Mattson ME, Furberg CF, Elinson J, eds. Assessment of quality of life in clinical trials of cardiovascular therapies. New York: Le Jack Publishing; 170-183
33. van den Berg G, Veldhuis JD, Frolich M, Roelfsema F 1996 An amplitude-specific divergence in the pulsatile mode of growth hormone (GH) secretion underlies the gender difference in mean GH concentrations in men and premenopausal women. J Clin Endocrinol Metab 81:2460-2467
34. Matzuda M, DeFronzo R 1999 Insulin sensitivity indices obtained from oral glucose tolerance testing. Diabetes Care 22:1462-1470
35. Nam SY, Kim KR, Cha BS, Song YD, Lim SK, Lee HC, Huh KB 2001 Low-dose growth hormone treatment combined with diet restriction decreases insulin resistance by reducing visceral fat and increasing muscle mass in obese type 2 diabetic patients. Int J Obes Relat Metab Disord 25:1101-1107
36. Sesmilo G, Biller BM, Llevadot J, Hayden D, Hanson G, Rifai N, Klibanski A 2000 Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency. A randomized, controlled clinical trial. Ann Intern Med 133:111-122
37. Burman P, Johansson AG, Siegbahn A, Vessby B, Karlsson FA 1997 Growth hormone (GH)-deficient men are more responsive to GH replacement therapy than women. J Clin Endocrinol Metab 82:550-555
38. Johannsson G, Oscarsson J, Rosen T, Wiklund O, Olsson G, Wilhelmsen L, Bengtsson BA 1995 Effects of 1 year of growth hormone therapy on serum lipoprotein levels in growth hormone-deficient adults. Influence of gender and Apo(a) and ApoE phenotypes. Arterioscler Thromb Vasc Biol 15:2142-2150
39. Johannsson G, Bengtsson BA 1998 Influence of gender and gonadal steroids on responsiveness to growth hormone replacement therapy in adults with growth hormone deficiency. Growth Horm IGF Res 8(Suppl B):69-75
40. Johannsson G, Albertsson-Wikland K, Bengtsson BA 1999 Discontinuation of growth hormone (GH) treatment: metabolic effects in GH-deficient and GH-sufficient adolescent patients compared with control subjects. Swedish Study Group for Growth Hormone Treatment in Children. J Clin Endocrinol Metab 84:4516-4524
41. Ferrara CM, Lynch NA, Nicklas BJ, Ryan AS, Berman DM 2002 Differences in adipose tissue metabolism between postmenopausal and perimenopausal women. J Clin Endocrinol Metab 87:4166-4170
42. Ottosson M, Vikman-Adolfsson K, Enerback S, Elander A, Bjorntorp P, Eden S 1995 Growth hormone inhibits lipoprotein lipase activity in human adipose tissue. J Clin Endocrinol Metab 80:936-941
43. Oscarsson J, Ottosson M, Eden S 1999 Effects of growth hormone on lipoprotein lipase and hepatic lipase. J Endocrinol Invest 22:2-9
44. Bengtsson BA, Eden S, Lonn L, Kvist H, Stokland A, Lindstedt G, Bosaeus I, Tolli J, Sjostrom L, Isaksson OG 1993 Treatment of adults with growth hormone (GH) deficiency with recombinant human GH. J Clin Endocrinol Metab 76:309-317
45. Bjorntorp P 1995 Endocrine abnormalities of obesity. Metabolism 44:21-23
46. Zachmann M, Fernandez F, Tassinari D, Thakker R, Prader A 1980 Anthropometric measurements in patients with growth hormone deficiency before treatment with human growth hormone. Eur J Pediatr 133:277-282
47. Johanson EH, Jansson PA, Lonn L, Matsuzawa Y, Funahashi T, Taskinen MR, Smith U, Axelsen M 2003 Fat distribution, lipid accumulation in the liver, and exercise capacity do not explain the insulin resistance in healthy males with a family history for type 2 diabetes. J Clin Endocrinol Metab 88:4232-4238
48. Goto T, Onuma T, Takebe K, Kral JG 1995 The influence of fatty liver on insulin clearance and insulin resistance in non-diabetic Japanese subjects. Int J Obes Relat Metab Disord 19:841-845
49. Elam MB, Wilcox HG, Solomon SS, Heimberg M 1992 In vivo growth hormone treatment stimulates secretion of very low density lipoprotein by the isolated perfused rat liver. Endocrinology 131:2717-2722
50. Rudling M, Parini P, Angelin B 1997 Growth hormone and bile acid synthesis. Key role for the activity of hepatic microsomal cholesterol 7α-hydroxylase in the rat. J Clin Invest 99:2239-2245
51. Marin P, Arver S 1998 Androgens and abdominal obesity. Baillieres Clin Endocrinol Metab 12:441-451
52. Jakicic JM 2003 Exercise in the treatment of obesity. Endocrinol Metab Clin North Am 32:967-980
53. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M; Finnish Diabetes Prevention Study Group 2001 Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343-1350